Detalhe da pesquisa
1.
Stepwise prolongation of overall survival from first to third generation EGFR-TKIs for EGFR mutation-positive non-small-cell lung cancer: the Tokushukai REAl-world Data project (TREAD 01).
Jpn J Clin Oncol
; 54(3): 319-328, 2024 Mar 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37997468
2.
Phase III study of adjuvant gemcitabine compared with adjuvant uracil-tegafur in patients with completely resected pathological stage IB-IIIA non-small cell lung cancer (WJTOG0101).
Int J Clin Oncol
; 26(12): 2216-2223, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34463869
3.
Combination of extracellular volume fraction by cardiac magnetic resonance imaging and QRS duration for the risk stratification for patients with non-ischemic dilated cardiomyopathy.
Heart Vessels
; 35(10): 1439-1445, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32417957
4.
ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor-naïve Japanese patients with EGFR mutation-positive non-small-cell lung cancer.
Cancer Sci
; 109(8): 2532-2538, 2018 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-29807396
5.
Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations.
Cancer Sci
; 109(9): 2852-2862, 2018 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29972716
6.
Use of hormone therapies in disseminated carcinomatosis of the bone marrow associated with hormone receptor-positive breast cancer.
Gynecol Endocrinol
; 34(4): 286-289, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29069999
7.
Bevacizumab for non-small-cell lung cancer: A nested case control study of risk factors for hemoptysis.
Cancer Sci
; 107(12): 1837-1842, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27714941
8.
Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients.
Jpn J Clin Oncol
; 46(5): 462-7, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-26977054
9.
Optimal strength and timing of steroids in the management of erlotinib-related skin toxicities in a post-marketing surveillance study (POLARSTAR) of 9909 non-small-cell lung cancer patients.
Int J Clin Oncol
; 21(2): 248-253, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26499382
10.
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
Lancet Oncol
; 15(11): 1236-44, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25175099
11.
Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer.
Cancer Sci
; 105(12): 1584-90, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25287435
12.
Phase II study of zoledronic acid combined with docetaxel for non-small-cell lung cancer: West Japan Oncology Group.
Cancer Sci
; 105(8): 989-95, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24837137
13.
Prognostic impact of concomitant pH-regulating drugs in patients with non-small cell lung cancer receiving epidermal growth factor receptor tyrosine kinase inhibitors: the Tokushukai REAl-world Data project 01-S1.
Cancer Chemother Pharmacol
; 2024 Apr 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38584202
14.
A phase II study of cisplatin /S-1 in patients with carcinomas of unknown primary site.
Invest New Drugs
; 31(6): 1568-72, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23975509
15.
A phase I study of S-1 with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer.
Invest New Drugs
; 31(3): 599-604, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22623066
16.
Early palliative intervention for patients with advanced cancer.
Jpn J Clin Oncol
; 43(8): 788-94, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23737605
17.
Gefitinib--a novel targeted approach to treating cancer.
Nat Rev Cancer
; 4(12): 956-65, 2004 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-15573117
18.
Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without bevacizumab in first-line advanced EGFR+non-small-cell lung cancer.
Transl Lung Cancer Res
; 12(6): 1167-1184, 2023 Jun 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37425411
19.
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.
J Clin Oncol
; 41(6): 1162-1171, 2023 02 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36791474
20.
A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903).
Cancer
; 118(24): 6126-35, 2012 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22674529